RT Journal Article
T1 Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
A1 Hochberg, Marc C
A1 Martel-Pelletier, Johanne
A1 Monfort, Jordi
A1 Möller, Ingrid
A1 Castillo, Juan Ramón
A1 Arden, Nigel
A1 Berenbaum, Francis
A1 Blanco, Francisco J
A1 Conaghan, Philip G
A1 Doménech, Gema
A1 Henrotin, Yves
A1 Pap, Thomas
A1 Richette, Pascal
A1 Sawitzke, Allen
A1 du Souich, Patrick
A1 Pelletier, Jean-Pierre
A1 MOVES Investigation Group, 
K1 Analgesics
K1 NSAIDs
K1 Osteoarthritis
AB To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. NCT01425853.
YR 2015
FD 2015-01-14
LK http://hdl.handle.net/10668/10493
UL http://hdl.handle.net/10668/10493
LA en
DS RISalud
RD Apr 11, 2025